Reply by Authors

Affiliations

¹ Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.
² Department of Obstetrics and Gynecology, Duke University, Durham.
³ Social, Statistical and Environmental Sciences Group, RTI International, Research Triangle Park, North Carolina.
⁴ Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego, La Jolla, California.
⁵ Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island.
⁶ Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, New Mexico.
⁷ Department of Women's Health, Dell Medical School, University of Texas, Austin, Texas.
⁸ Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama.
⁹ Obstetrics, Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio.
¹⁰ Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania.
¹¹ Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

Comment

Heidi S Harvie et al. J Urol. 2020 May.

. 2020 May;203(5):977.

doi: 10.1097/JU.0000000000000656.02. Epub 2020 Feb 11.

¹ Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.
² Department of Obstetrics and Gynecology, Duke University, Durham.
³ Social, Statistical and Environmental Sciences Group, RTI International, Research Triangle Park, North Carolina.
⁴ Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego, La Jolla, California.
⁵ Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island.
⁶ Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, New Mexico.
⁷ Department of Women's Health, Dell Medical School, University of Texas, Austin, Texas.
⁸ Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama.
⁹ Obstetrics, Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio.
¹⁰ Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania.
¹¹ Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

No abstract available

Comment on

Editorial Comment.
Sutherland SE. Sutherland SE. J Urol. 2020 May;203(5):976. doi: 10.1097/JU.0000000000000656.01. Epub 2020 Feb 11. J Urol. 2020. PMID: 32073932 No abstract available.

1. Ginsberg DA, Drake MJ, Kaufmann A et al.: Long-term treatment with onabotulinumtoxinA results in consistent, durable improvements in health related quality of life in patients with overactive bladder. J Urol 2017; 198: 897. - PubMed
1. Dowson C, Watkins J, Khan MS et al.: Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012; 61: 834. - PubMed
1. Veeratterapillay R, Hardling C, Teo L et al.: Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injection for detrusor overactivity. Int J Urol 2014; 21: 175. - PubMed
1. Nitti VW, Ginsberg D, Sievert KD et al.: Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol 2016; 196: 791. - PubMed